Purpose Facilitation of the ability of neuronal lineages derived from transplanted stem cells to differentiate is essential to improve the low efficacy of neuronal differentiation in stem cell therapy in vivo. Neurogenin 1 (Ngn1), a basic helix-loop-helix factor, has been used as an activator of neuronal differentiation. In this study, we monitored the in vivo activation of neuronal differentiation by Ngn1 in neuronal precursor cells using neuron-specific promoter-based optical reporters.
Introduction
The use of multipotent stem cells to restore damaged tissue in stem cell therapy has been well documented. With their effective differentiation potential, neural stem cells (NSCs) or neural precursor cells may provide the ideal cell source for the treatment of neurodegenerative diseases of the brain. Transplantation of NSCs or neuronal precursor cells has the potential to restore the functional deficits associated with Hyun Jeong Oh and Do Won Hwang contributed equally to this work.
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injury to the central nervous system [1] . Cell replacement and gene transfer to the injured brain have provided an ideal source of new therapeutic strategies for human neurodegenerative diseases including Parkinson's disease, Huntington's disease, and Alzheimer's disease [1] [2] [3] [4] [5] [6] . Indeed, intravenously transplanted human NSCs effectively migrate to the damaged region, differentiate into neurons and astrocytes, and ultimately induce functional improvement in rats with focal cerebral ischaemia [7, 8] .
Although stem cell-based research has been intensive, the low efficiency of differentiation of stem cells into functioning neuronal cells has hampered functional improvements. Therefore, the development of critical factors to promote neuronal differentiation by modulating endogenous neuronspecific genes is necessary for effective stem cell-based therapy. Neurogenin 1 (Ngn1) is a basic helix-loop-helix transcription factor that is expressed in early neuronal progenitor cells during the development of the nervous system [9] . The overexpression of Ngn1 increases the number of neuronal cells in Xenopus embryos and in uncommitted pluripotent stem cells, e.g. embryonic carcinoma P19 cells, by the activation of downstream proneural basic helix-loop-helix transcription factors, including NeuroD [10] . Ngn1 suppresses gliogenesis by sequestering CREB binding protein/p300 and Smad1 away from the signal complexes that are required for the expression of glial fibrillary acidic protein [9, 11] . Kim et al. reported that the overproduction of Ngn1 alone is sufficient to induce neurite outgrowth in F11 neuronal precursor or mouse embryonal carcinoma P19 cells [10, 12] . F11 cells are a hybrid cell line between neuroblastoma N18TG2 and dorsal root ganglionic neurons. These cells have unique characteristics in that they can differentiate into neuron-like cells in the presence of cAMP and express various neuron-specific markers, including specific receptors for prostaglandin and Ntype and L-type voltage-dependent Ca 2+ channels, suggesting that F11 cells are similar to neuronal precursor cells [13] .
An in vivo molecular imaging approach has emerged as a powerful technique to identify the in vivo characteristics of implanted cells. To assess the location and proliferation or differentiation of the grafted stem cells in vivo, molecular markers, e.g. β-galactosidase, alkaline phosphatase and green fluorescent protein, are used for immunochemical detection or in situ hybridization, particularly to prove the localization or neuronal commitment of grafted cells [14] [15] [16] [17] [18] [19] [20] . However, this method is too invasive and requires a tissue biopsy, which is difficult to repeat in the same animal. The application of in vivo noninvasive and quantifiable methods to estimate the differentiation potential of stem cells in vivo could provide important information at the level of small animals. Previously, we have reported a new noninvasive method to evaluate neuronal differentiation in vivo and in vitro by examining the expression of a reporter gene under the transcriptional control of a neuron-specific promoter in F11 cells [14] . In the present study, we monitored the activation process of neuronal differentiation induced by the neuronal activator Ngn1 using optical imaging reporters coupled to the NeuroD promoter in the mouse brain and subcutaneous regions.
Materials and methods

Plasmid DNA vectors
The plasmid vector containing full-length mouse Ngn1 cDNA was provided by Professor Haeyoung Suh-Kim, Ajou University. Full-length Ngn1 cDNA (GenBank U63841) was obtained by polymerase chain reaction (PCR) using the oligonucleotides TGC AAG ATG CCT GCC CCT TT (forward) and GCC ATA GGT GAA GTC TTC TGA AGC CGA GGG ACT ACT G (reverse) and subcloned into the pCR2.1-TOPO plasmid. The cDNA was inserted into the EcoR I site of pcDNA3.1/His (B) to yield pcDNA/His-Ngn1 [10] . pNeuroD(-2.2)-Fluc contained a firefly luciferase reporter gene under the control of 2.2 kb of the mouse NeuroD promoter. This reporter gene contains cis-elements for the tissue-specific expression of NeuroD in the nervous tissue and pancreatic islets [21] .
Cell culture and transfection protocol F11 cells, rat dorsal root ganglion and mouse neuroblastoma hybrid cells, and HeLa cells (human cervical cancer cells) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % fetal bovine serum (FBS; Gibco, Grand Island, NY), 10 U/ml penicillin, and 10 μg/ml streptomycin. The cells were maintained at 37°C in a humidified atmosphere containing 5 % CO 2 . We plated 1.5×10 5 F11 cells in six-well plates. The pNeuroD(-2.2)-Fluc reporter gene, pcDNA/His-Ngn1 and pcDNA3.1/His(B) were transfected into F11 cells using Lipofectamine (Invitrogen, Carlsbad, CA) and diluted in OPTI-MEM medium (Gibco, Grand Island, NY). The transfected cells were incubated in DMEM supplemented with 0.5 % FBS for 2 or 3 days.
Quantitative analysis of the expression of neuronal markers using quantitative reverse transcription PCR Using Trizol (Invitrogen, Grand Island, NY), total RNA was isolated during the neuronal differentiation of F11 cells. Total RNA (1 μg/ml) was reverse-transcribed using reverse transcriptase (Invitrogen, Carlsbad, CA) for quantitative reverse transcription PCR (qRT-PCR) analysis. qRT-PCR was performed using neuron-specific primers ( Table 1) . The PCRs were performed in triplicate using an ABI® 7500 (Life Technologies, Carlsbad, CA) with EvaGreen qPCR Mastermix (Applied Biological Materials, Richmond, BC, Canada). The reactions were incubated at 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. To normalize the experimental samples, β-actin was used as a control.
Immunofluorescence staining
Mock-treated and Ngn1-treated F11 cells were seeded onto coverslips in six-well plate. After discarding the medium and rinsing with phosphate-buffered saline (PBS), the cells were fixed with 4 % paraformaldehyde (PFA) in PBS for 15 min at room temperature. The cells were then washed three times with PBS and incubated in 0.5 % H 2 O 2 in MeOH for 5 min at 20°C. After washing with PBS three times, the cells were treated with 0.5 % Triton X-100 in PBS for 5 min at 4°C. The samples were rinsed three times with PBS and nonspecific binding sites were blocked with 1 % normal horse serum in PBS for 1 h at room temperature. Anti-Tuj-1 (1:1,300 dilution; Cell Signaling, Danvers, MA), anti-NeuroD (1:500 dilution; Abcam, Cambridge, FL), anti-MAP2 (1:1,000 dilution; Sigma, Saint Louis, MO), anti-NF-M (1:2,000 dilution; Sigma, Saint Louis, MO) and anti-NeuN (1:100 dilution; MILLIPORE, Temecula, CA) antibodies were diluted in PBS and incubated with the samples at 4°C overnight. Alexa Fluor 488-conjugated antimouse and anti-rabbit secondary antibodies (Invitrogen, Grand Island, NY) were used to visualize the antibody reactions. Nuclei were counterstained with 4′-6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA) and observed at 461 nm. Fluorescent images were acquired using a confocal laser scanning microscope (LSM 510; Carl Zeiss, Jena, Germany).
Quantitative analysis of the expression of neural markers Confocal data were used for quantitative analysis using TissueFAXS2.0 (TissueGnostics, Vienna, Austria). First, the field of view for the areas of interest was set after prescanning to identify tissue sections. The fluorescence signals from the areas of interest were detected using TissueFAXS2.0. TissueFAXS yields rapid high-resolution images of tissue sections for subsequent analysis. Quantitative analysis was performed using TissueQuest3.0, the cell analysis software for fluorescence images.
In vitro luciferase assay F11 and HeLa cells were washed with PBS and lysed using a lysis buffer (Promega, Madison, WI) at 48 h after transfection. The cell lysates were collected with a cell scraper and redistributed into a 96-well plate. The luciferase assay was carried out using a luciferase assay kit (Promega, Madison, WI). The bioluminescence intensity of each cell lysate was measured using a microplate luminometer (TR717, Applied Biosystems; Life Technologies, Carlsbad, CA). Luciferase activity was normalized by protein content.
In vivo bioluminescence imaging First, at 24 h after transfection with the pNeuroD-Fluc and pCMV-Gluc vectors, F11 cells were detached by trypsinization and harvested in PBS. An in vivo-jetPEI TM system (Polyplustransfection, NY, USA) was used for in vivo gene delivery. A volume of 100 μl containing 1.5×10
6 cells was injected subcutaneously (s.c.) into the right thigh of male BALB/c nude mice with in vivo-jetPEI-Ngn1 complexes and into the left thigh with in vivo-jetPEI-Mock complexes (n=4). The mice were anaesthetized with 10 μl Zoletil/Rumpun (2:1) solution, and 3 mg D-luciferin suspended in 100 μl PBS was injected intraperitoneally 10 min before the acquisition of the bioluminescence images. Whole-body images for Fluc activity were acquired after 10 min. The Gluc signal from the Gaussia luciferase gene, which is under the control of the cytomegalovirus (CMV) promoter, was used for Fluc signal normalization. To acquire Gluc images, 12 h after the Fluc images were acquired, 5 μg coelenterazine substrate (Biotium, Hayward, CA) was injected directly into the implanted F11 cells of the subcutaneous region. The Gluc images were acquired 1 min after coelenterazine injection. The mice were then placed in an IVIS-100 imager (Xenogen, Alameda, CA). Bioluminescence images for Fluc activity were acquired 10 min after intraperitoneal injection of D-luciferin. The Fluc and Gluc signals were analysed quantitatively by region of interest (ROI). ROI values were normalized by dividing the firefly luciferase activity for pNeuroD-Fluc by the Gaussia luciferase signal for the pCMVGluc vector in each Ngn1 and Mock treated F11 cell group. The normalized value of day 0 calculated as the Fluc/Gluc activity was set to 1, and then the signal intensity of each day was divided by the mean of Fluc/Gluc activity of day 0.
In vivo bioluminescence imaging for orthotopic implantation
For the in vivo imaging study of the brain, F11 cells transfected with the pNeuroD-Fluc vector in a T75 flask Table 1 List of neuron-specific qRT-PCR primers and their sequences used in the study
were harvested by trypsinization. The cells were spun, rinsed, and resuspended in 500 μl PBS. A CM-DiI celllabelling solution (Life Technologies, Carlsbad, CA) was mixed directly with PBS (2 μl CM-DiI labelling solution per millilitre of solution). The F11 cells were then incubated with CM-DiI/PBS for 20 min at 37°C. Six BALB/c nude mice were injected stereotactically with 4.5×10 5 CM-DiI-labelled cells in a total fluid volume of 5 μl PBS into the right striatum (coordinates: anteroposterior 0.5, mediolateral 1.5, dorsoventral 2.0) with in vivo-jetPEI-Ngn1 complexes or in vivo-jetPEIMock complexes. Quantitative ROI data from the acquired bioluminescence images are expressed as photons per second per square centimetre per steradian.
Histology and immunohistochemistry
The mice were killed using CO 2 3 days after cell transplantation. The F11 cells injected s.c. into the thighs were removed and postfixed with 4 % PFA. After fixation, the isolated F11 cells were embedded in paraffin and 4 μm-thick sections were prepared. The brains were removed surgically, embedded in OCT, and frozen on a bed of liquid nitrogen. Serial (10 μm thick) cryosections were prepared and some of the cryosections were stained with haematoxylin and eosin. For immunohistochemistry, the sections were blocked with 1 % normal goat serum in PBS for 1 h at room temperature. The sections were then incubated with antibodies against Tuj-1 (1:100 dilution), NeuroD (1:500 dilution), MAP2 (1:100 dilution), NF-M (1:2,000 dilution) and NeuN (1:100 dilution) at 4°C overnight. The primary antibody reactions were visualized with Alexa Fluor 488-conjugated anti-mouse and anti-rabbit secondary antibodies (Invitrogen, Grand Island, NY). Fluorescent signals were detected using the LSM 510 confocal laser scanning microscope.
Statistical analysis
Data are displayed as means ± standard deviation (SD) and were assessed using Student's t test. Statistical significance was accepted at P values <0.05.
Results
Induction of neurite outgrowth by overproduction of Ngn1 in F11 cells
To confirm the potential ability of neurogenic Ngn1 to induce neuronal differentiation, F11 cells were treated with a Mock or Ngn1-containing plasmid vector for 1 or 3 days to promote neuronal differentiation. The Mock vector was the pcDNA3.1/His expression vector of Ngn1 that does not contain Ngn1 cDNA, and was used as a negative control. F11 cells were transfected with the Ngn1 transgene under two different serum concentrations to determine the optimal condition to induce the activation of neuronal differentiation by Ngn1.
Because the optimal condition for neural induction has been reported to be 0.5 % FBS [12] , 0.5 % and 10 % FBS conditions were used. Mock-transfected and Ngn1-transfected F11 cells (F11-Mock and F11-Ngn1 cells, respectively) were incubated for either 1 or 3 days in 0.5 % or 10 % FBS. The round cell shape morphology was unchanged in F11-Mock cells, indicating their undifferentiated state. In addition, there was no significant change of F11 cell morphology in the groups treated with Ngn1 or Mock in 10 % FBS (data not shown) and Mock in 0.5 % FBS (Fig. 1a, c) . In contrast, a significant neurite outgrowth pattern was observed in F11-Ngn1 cells incubated in DMEM containing 0.5 % FBS (Fig. 1b, d ). The lengths of neurite outgrowths were also estimated quantitatively from differential interference contrast images of the confocal analysis of F11-Mock and F11-Ngn1 cells in 0.5 % FBS. Individual neurite outgrowth lengths were measured using LSM Image Examiner and showed a distinct pattern between F11-Mock and F11-Ngn1 cells (n=20). Neurite outgrowths in F11-Ngn1 cells were, on average, 16-fold longer than those in F11-Mock cells 3 days after Mock or Ngn1 treatment (Fig. 1e) .
Measurement of neuron-specific gene expression after neuronal activation by treatment with Ngn1
To investigate the ability of Ngn1 to activate neuronal differentiation, we first examined changes in the mRNA expression levels of a variety of neuron-specific genes at each neuronal developmental stage, including early and late neuronal markers. The expression levels of the early neuronal marker Tuj-1 and the late neuronal genes NeuroD, MAP2 and NF-M were evaluated using real-time RT-PCR analysis. Because dramatic neurite outgrowth was induced by Ngn1 in 0.5 % FBS, RNA was isolated from F11 cells that were maintained in DMEM containing 0.5 % FBS after transfection with the Mock or Ngn1 expression plasmid vector. Quantitative analysis by real-time RT-PCR revealed increased expression levels of Tuj-1, NeuroD, MAP2 and NF-M, but not of the neuronal nuclear antigen (NeuN), in F11-Ngn1 cells compared to F11-Mock cells (Fig. 2a ). An immunostaining assay was also conducted to confirm whether Ngn1 overproduction induces neuronal differentiation at the protein level. Highly specific expression of early and late neuronal markers, i.e. Tuj-1, NeuroD, MAP2 and NF-M, was found in the cytoplasm of F11-Ngn1 cells, but they were expressed at minimal levels in F11-Mock cells. In addition, nuclear expression of Ngn1 was detected in F11-Ngn1 cells (Fig. 2b) . However, NeuN, a mature neuronal marker that is expressed in the final stage of neuronal differentiation, was not expressed in F11-Ngn1 cells, indicating that these cells do not reflect the last stage of neuronal differentiation, at least in an in vitro environment.
To examine the changes in neuron markers induced by Ngn1 more accurately, a TissueFAX imaging analyser, which is an imaging microscope with the facility for quantitative analysis, was used to acquire total fluorescence signals from whole cells on a slide glass. Consistent with the immunostaining results, the immature neuronal marker Tuj-1, the mature neuronal marker NeuroD, and neuronspecific cytoskeletal protein NF-M exhibited approximately 2.5-fold, 1.8-fold, and 5.6-fold increased expression levels, respectively (data not shown). In particular, the MAP2 marker showed the greatest increase in expression when the Ngn1 gene was overexpressed. These data were significantly correlated with the higher levels of MAP2 expression in the cytoplasm of F11-Ngn1 cells, as measured by immunocytochemistry. These results indicate that Ngn1 overexpression alone in F11 cells is sufficient to induce neuronal cell fate with changes in neuronal markers as well as in neuron-specific phenotypes.
Evaluation of the effect of Ngn1 using a neuronal promoter-driven reporter gene A recombinant plasmid DNA vector carrying the firefly luciferase gene regulated by the NeuroD promoter (pNeuroDFluc) was designed to examine the activation of neuronal differentiation by Ngn1. HeLa cells, which have nonneuronal characteristics, were chosen as a negative control to confirm that the NeuroD promoter was influenced only by the overproduction of Ngn1. F11 and HeLa cells were transiently transfected with Mock or Ngn1 and pNeuroD-Fluc as a reporter gene. F11 cells cotransfected with both Ngn1 and pNeuroD-Fluc genes exhibited approximately 11-fold higher luciferase activity than F11-Mock cells (Fig. 3a) . In contrast, only 1.6-fold higher luciferase signals were observed in HeLa cells overexpressing Ngn1 compared to Mock-transfected HeLa cells. These results indicate that although the activation of the NeuroD promoter was, to a certain degree, affected by In vivo bioluminescence imaging to analyse the effect of Ngn1 in implanted F11 cells
To monitor the activation pattern of neuronal differentiation in vivo by the induction of Ngn1, 1.5×10 6 F11 cells were collected in 100 μl PBS after transfection with the pNeuroD-Fluc vector. The Gaussia luciferase gene driven by the CMV promoter (pCMV-Gluc) was also used as an internal control for in vivo normalization. As for the in vivo delivery of the transgene, we used the in vivo-jetPEI system, which is an in vivo delivery reagent for efficient nucleic acid delivery in many species, including the mouse and rabbit.
First, to evaluate the efficiency of transgene delivery into F11 cells using the in vivo-jetPEI system, a retroviral vector carrying the enhanced luciferase (effluc) gene was tested in F11 cells. After the effluc vector was mixed with 20 μl in vivo-jetPEI for 15 min, F11 cells were injected s.c. into the right thigh of male BALB/c nude mice with in vivo-jetPEI-effluc vector complexes. Bioluminescence signals in the injected region were detected at 24 and 48 h after injection (data not shown). After pNeuroD-Fluc and pCMV-Gluc-transfected F11 cells mixed with in vivo-jetPEI-Ngn1 complexes or in vivo-jetPEI-Mock complexes were injected into the thighs of nude mice, serial images were acquired using an in vivo optical imaging device. The F11-Ngn1-injected group (right thigh) showed higher luciferase intensity than the F11-Mock-injected group at 2 and 3 days after injection. In contrast, Gluc activity in the right thigh of the F11-Ngn1 group gradually decreased (Fig. 3b) , possibly because the proliferation rates of the F11-Ngn1 group might be reduced continuously due to the induction of neuronal differentiation by Ngn1. The ROI value was calculated by dividing the firefly luciferase activity of pNeuroD-Fluc by the Gaussia luciferase signal of the pCMV-Gluc vector in the F11-Ngn1 and F11-Mock groups. The ROI value for the Fluc/Gluc activity ratio indicated that the luciferase signal in the F11-Ngn1 group increased continuously compared to the F11-Mock group (Fig. 3c ). These results demonstrate that the increased luciferase activity in the F11-Ngn1 group was due to the activation of neuronal differentiation by Ngn1 in the transplanted F11 cells.
To verify the activation of in vivo neuronal differentiation of the grafted F11 cells by Ngn1, we performed immunohistochemistry analysis for Ngn1 and neuronal-specific markers, i.e. Tuj-1, NeuroD, MAP2, NF-M and NeuN. At 3 days after the in vivo bioluminescence images were acquired, the injected F11 cells were isolated from the subcutaneous region for the immunohistochemistry assay. The expression of most of the neuron-specific markers, including NeuroD, was increased dramatically in the F11-Ngn1-implanted region. In contrast, under the same conditions, these neuron-specific proteins were expressed at minimal levels in the F11-Mock-implanted region. We also performed quantitative analysis of the immunohistochemistry assay using TissueFAXS2.0, and showed increased expression of the neuron-specific markers, including NeuroD, except for NeuN, in the F11-Ngn1 group ( Supplementary Fig. 1 ). Interestingly, consistent with the in vitro immunofluorescence staining results, no fluorescent signal for NeuN expression was found, even in the F11-Ngn1 group (Fig. 3d) . These results indicate that the s.c. implanted F11-Ngn1 cells were successfully induced into a neuronal cell lineage, but not the final stage of neuronal differentiation.
In vivo orthotopic implantation of F11 cells to examine the activation of neuronal differentiation in the brain To evaluate the possibility of inducing neuronal activation of cells implanted in the brain, we injected of F11 cells transfected with pNeuroD-Fluc orthotopically into the right striatum region of nude mice after mixing them with in vivojetPEI-Ngn1 or in vivo-jetPEI-Mock complexes. In addition, to track the injected F11 cells in the brain, they were stained with the fluorescent tracker CM-DiI (Life Technologies, Carlsbad, CA) before transplantation into the brain. At 3 days after the cells were injected intracranially, we detected a significant difference in brain luciferase intensity between the F11-Ngn1 and F11-Mock groups (Fig. 4a) . Quantitative analysis of the bioluminescence signal ratio (each day/0 day ratio) revealed similar luciferase intensity between the F11-Ngn1 and F11-Mock implantation groups up to 2 days after cell implantation. However, the luciferase intensity ratio was significantly increased at 3 days in the F11-Ngn1 group (Fig. 4b) . Thus there was a somewhat different pattern of luciferase signal between the groups implanted in subcutaneously and those implanted in brain tissue.
For immunohistochemistry assay, brain tissue was also isolated at 3 days after bioluminescence imaging. Ngn1 was expressed only in the F11-Ngn1 group. Increased expression of the neuron-specific markers Tuj-1, NeuroD, MAP2 and NF-M was found in the implanted F11-Ngn1 cells. The fluorescence signal for the neuronal markers was matched with the DiI fluorescence signal. Interestingly, compared with the results acquired from in vitro immunostaining and the in vivo subcutaneous injection study, high expression of the late neuronal marker NeuN was detected in brain sections from the F11-Ngn1 group (Fig. 4c) . This result indicates that the brain environment surrounding the implanted cells can induce a different neuronal differentiation ability compared to the subcutaneous regions of mice.
Quantitative analysis by TissueFAXS2.0 for the expression of immature and mature neuron-specific markers also supported the activation of neuronal differentiation more accurately than the immunostaining data. Consistent with the immunostaining findings, the immature neuronal marker Tuj-1 and mature neuronal marker NeuroD showed approximately 1.6-and 38-fold increases in their expression levels, respectively ( Supplementary Fig. 2 ). The expression of the neuron-specific cytoskeletal protein NF-M was 3.2-fold higher than in the F11-Mock group. In particular, MAP2 was expressed at the highest levels of all the examined neural markers. The TissueFAXS analysis data were consistent with the immunohistochemistry findings, indicating increased expression of neuronal markers in F11-Ngn1 cells isolated from the brain.
Discussion
The in vivo differentiation imaging approach may provide useful information for the evaluation of differentiation efficacy of novel differentiation-inducing factors and for a better understanding of the therapeutic mechanism involved in stem cell-based therapy, for example in Parkinson's disease [22, 23] . However, since grafted stem cells differentiate into functioning neurons in vivo with low efficiency, effective neuron-inducing factors need to be developed to enhance their therapeutic efficacy. In this study, we used the neurogenic transcription factor Ngn1 that represses gliogenesis directly and activates neurogenesis simultaneously by promoting the expression of NeuroD, and it may be an ideal candidate for facilitating the induction of neuronal differentiation [9] . In this study, we showed that 5 cells transfected with pNeuroD-Fluc were injected stereotactically into the right striatum of nude mice with in vivo-jetPEI-Ngn1 complexes or in vivo-jetPEIMock complexes (six mice). Bioluminescence images were acquired from 0 to 3 days. Enhanced bioluminescence signals in the F11-Ngn1 group were detected at 3 days after implantation. b ROI values are expressed as the each day/0 day ratio. Significantly increased luciferase intensity was seen in the F11-Ngn1 group at 3 days after implantation.
Data are expressed as means±SD. c Ex vivo validation study for the activation pattern of neuronal differentiation in brains implanted with F11-Ngn1 cells. Brain tissue isolated from nude mice at 3 days after cell transplantation was fixed with 4 % formaldehyde. Neuron-specific antibodies against the transcription factor Ngn1, the early neuronal marker Tuj-1, and the mature neuronal markers NeuroD, MAP2, NF-M and NeuN were used to analyse the degree of neuronal differentiation induced by Ngn1 in the brain. The expression of all the markers is shown in green. Scale bars 20 μm Ngn1 activated neuronal differentiation in a validation study with a variety of neuron-specific markers in neuronal precursor F11 cells. We also established an in vivo imaging system to track the activation process of the grafted cells into a neuronal lineage using optical luciferase regulated by a neuron-specific promoter. Using this system, we observed a significant change in F11 cells to a neuronal phenotype from the overexpression of the Ngn1 gene alone and culture in medium with a low percentage of FBS. A low concentration of FBS, which reduces cell growth, is one of the critical factors that accelerates differentiation of neuronal precursor cells. Neuronal gene expression profiling with real-time RT-PCR was used to confirm whether the morphological changes induced by Ngn1 were caused by the extreme stress of exogenous gene transfection. In this study, we found enhanced expression of several neuron-specific genes including NeuroD in F11-Ngn1 cells. Quantitative analysis by real time RT-PCR showed increased expression levels of the early neuronal marker Tuj-1,, and the mature neuronal markers NeuroD, MAP2 and NF-M, but not of neuronal nuclear antigen (NeuN) in F11-Ngn1 cells, compared to in F11-Mock cells (Fig. 2a) .
It is of interest that Ngn1 activated neuronal differentiation in the neuronal precursor cells within a short period of time. This result indicates that it is not necessary to use a virus-based construct for long-term transgene expression; indeed, virus-mediated transduction may cause insertional mutagenesis or unexpected side effects [24, 25] . Transient transfection techniques using plasmid DNA vectors are also problematic in that they do not show the long-term effect of the transgene due to their "dilution" when the cells start to undergo division. However, since activation of neuronal differentiation by Ngn1 occurred in a short period of time, the use of a plasmid vector encoding Ngn1 in this study was suitable in terms of safety.
The immunofluorescence staining results also supported the activation of neuronal differentiation by Ngn1, showing enhanced expression of late neuronal proteins as well as early neuronal markers. In particular, the expression levels of MAP2, which forms the neuronal cytoskeleton, showed the greatest difference between Mock and Ngn1 induction. We analysed the differences in expression of various neuronspecific markers related to different neuronal stages between the F11-Mock and F11-Ngn1 groups, and more accurately analysed neuronal differentiation using quantitative measurements based on individual fluorescence. These analyses provided reliable information on the extent of differentiation induced by Ngn1 according to neuronal stage. In particular, the process of acceleration into the neuronal lineage in vivo was monitored successfully in the mouse model via orthotopic as well as subcutaneous injection of neuronal precursor cells.
To deliver the transgene of interest into cells in vivo, an efficient in vivo gene delivery system is required. In this study, we utilized the cationic polyethyleneimine (PEI) polymer that has been widely used for gene delivery in vivo [26, 27] . In a previous study, there was no induction of major proinflammatory cytokines such as TNF-α, IL-6, and IL-12/IL-23 using the in vivo-jetPEI system for systemic delivery of DNA and siRNA in vivo compared to other lipophilic reagents [28] . Therefore, we used the in vivojetPEI system for our in vivo systemic delivery experiments instead of Lipofectamine. After the effective delivery of the transgene via in vivo-jetPEI was verified using a general luciferase viral vector system, F11 cells carrying pNeuroDFluc and pCMV-Gluc vectors were mixed with Ngn1 or Mock complexes with the in vivo-jetPEI and then injected into each thigh of nude mice. The luciferase signal in F11 cells treated with Mock vector was comparable to that in F11 cells treated with Ngn1 vector at day 0 (Fig. 3b) . This was because we used F11 cells that already had some degree of neuronal characteristics and thus basal Fluc activity even with Mock treatment, enabling us to be confident that similar amounts of F11 cells were injected into both thighs at the start. Acquired serial images indicated a higher luciferase signal over time in the thigh injected with F11-Ngn1 cells than in the thigh injected with F11-Mock cells, which decreased gradually. In contrast, the Gluc signal from F11-Ngn1 cells decreased gradually up to 3 days, while the Gluc signal from F11-Mock cells tended to increase after Mock treatment up to 2 days and decreased on day 3 (Fig. 3b) . These results indicate that the in vivo induction of Fluc signal by Ngn1 effectively represents its functional action in differentiating the grafted cells into the neuronal lineage, irrespective of proliferation of the grafted cells which would have varied after Mock treatment and would have reduced after Ngn1 treatment. These findings were also supported by the immunohistochemistry results.
In the in vitro study the expression of the early neuronal marker Tuj-1 and mature neuronal markers MAP2 and NeuroD were significantly enhanced in F11-Ngn1 cells, but not in F11-Mock cells (Fig. 2b) . In addition, neuronal differentiation was activated in F11 cells isolated from the subcutaneous and brain injection sites, and these cells expressed Tuj-1, NeuroD, MAP2 and NF-M (Figs. 3d and 4c ). In contrast, NeuN, which is a late neuronal marker, was not expressed even after Ngn1 induction in the subcutaneous area or in vitro. However, F11-Ngn1 cells in the brain showed significantly increased NeuN expression. This result demonstrates that F11-Ngn1 cells injected into the brain, which contains various neuronal and glial cell populations, may be affected by various factors secreted from host neuronal or glial cells, allowing the progression of neuronal differentiation.
In the optical imaging analysis of the brain, in vivo normalization of implanted F11 cells using Gaussia luciferase expression was not possible because coelenterazine, the substrate for Gaussia luciferase, cannot penetrate the blood-brain barrier. Thus, the development of a novel luciferase substrate that is able to cross the blood-brain barrier, and is similar to D-luciferin, is necessary for in vivo optical imaging in the brain.
The neuron-specific reporter imaging technique offers powerful information to track the time-course of neuronal differentiation using a noninvasive approach. Our approach to in vivo imaging for assessing the activation of neuronal differentiation by a neuron-inducing gene may be applicable to the development of stem cell therapies. The in vivo extent of neuronal differentiation of grafted cells can be determined easily. In addition, this monitoring system may be useful for determining the ability of candidate Ngn1-like neuronalinducing factors to promote neuronal differentiation in vivo. Moreover, in terms of the enhancement of the efficacy of gene-based therapy, an in vivo imaging strategy for tracking the activation of neuronal differentiation induced by a neuronal activator may help elucidate the therapeutic mechanisms underlying findings of behaviour analysis showing functional improvement. The ability to monitor the activation of neuronal differentiation by Ngn1 may be helpful in determining therapeutic effectiveness in a variety of neurological diseases.
